Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial
Authors
Keywords
-
Journal
Lancet Respiratory Medicine
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-02-04
DOI
10.1016/s2213-2600(22)00006-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy
- (2021) Linda Petrone et al. JOURNAL OF INFECTION
- Baricitinib Therapy in Covid-19 Pneumonia — An Unmet Need Fulfilled
- (2021) Delia Goletti et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
- (2021) Obbina Abani et al. LANCET
- Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials
- (2021) Dimitrios Patoulias et al. CLINICAL RHEUMATOLOGY
- A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD–0903) in severe COVID-19
- (2021) Dave Singh et al. EUROPEAN RESPIRATORY JOURNAL
- Baricitinib reduces 30‐day mortality in older adults with moderate‐to‐severe COVID ‐19 pneumonia
- (2021) Pedro Abizanda et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
- (2021) Patrícia O. Guimarães et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibitors — More Than Just Glucocorticoids
- (2021) Justin Stebbing et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial
- (2021) Andre C Kalil et al. Lancet Respiratory Medicine
- Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial
- (2021) Vincent C Marconi et al. Lancet Respiratory Medicine
- Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword
- (2021) Li Yin Tan et al. Frontiers in Immunology
- Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
- (2020) Peter Richardson et al. LANCET
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- COVID-19: combining antiviral and anti-inflammatory treatments
- (2020) Justin Stebbing et al. LANCET INFECTIOUS DISEASES
- Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
- (2020) Yang Cao et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19
- (2020) Yang Yang et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
- (2020) Fabrizio Cantini et al. JOURNAL OF INFECTION
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
- (2020) Fei Zhou et al. LANCET
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of Baricitinib in Patients with Moderate and Severe COVID-19
- (2020) Boghuma K Titanji et al. CLINICAL INFECTIOUS DISEASES
- Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study
- (2020) Fabrizio Cantini et al. JOURNAL OF INFECTION
- Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19
- (2020) Jonathan T. Sims et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Case Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation. A Meta-analysis
- (2020) Zheng Jie Lim et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes
- (2020) Rajendra Karki et al. CELL
- Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques
- (2020) Timothy N. Hoang et al. CELL
- Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19
- (2020) Yapeng Su et al. CELL
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
- (2020) Andre C. Kalil et al. NEW ENGLAND JOURNAL OF MEDICINE
- The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers
- (2014) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started